B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031

Access and explore the following in-depth insights from the ‘B-Cell Non-Hodgkins Lymphoma Cell Therapy Market’ report:

• Disease epidemiology including – Patient segmentation, staging & progression rates, and Disease incidence/prevalence.
• Marketed products with a breakdown established versus cell therapies, backed with primary research validated base year forecast
• Commercial assessment and Forecast by number of patients treated per class and future sales projection based on competitive assessment
• Launch date assessment with estimated launch dates by class of cell therapy and indication-specific assumptions.
• Evaluation of indication-specific unmet needs, competitive assessment, and identifies key future players in the cell therapy market.
• Pipeline products covering the following –
  • Early- to late-stage pipeline drugs
  • Breakdown by class of cell therapy
  • Ten-year sales projection
  • Likelihood of approval analysis
  • Breakdown by target

How is the ‘B-Cell Non-Hodgkins Lymphoma Cell Therapy Market’ report different from other reports in the market?

• Access updated epidemiology for patient populations relevant to cell therapy in 2021-2031
• Review updated prescription habits at the class level for already established therapies and compare their future projections to cell therapy pipeline drugs.
• Full market assessment in the 8MM of all currently marketed and late-stage pipeline cell therapy drugs with drug-level forecasts, supplemented by class-level forecasts for early-stage molecules
• Explore indication-specific top-line sales forecasts across 15 countries, in the 8MM and Australia, Belgium, Canada, Denmark, Israel, South Korea, and Switzerland, facilitating global R&D and investment strategies in countries that may be particularly promising for cell therapies
• Compare region-and indication-specific market shares for prescribed drugs in NHL to identify market size and potential outside the 8 major markets

We recommend this valuable source of information to anyone involved in:

• Pharmaceutical companies
• Biotech
• CMOs, CMOs, CDMOs
• Consulting Companies
• Professional Services (e.g., Investment, Equity Companies, Banks)

To get a snapshot of the B-Cell Non-Hodgkins Lymphoma Drugs Market report, download a free report sample

B-Cell Non-Hodgkins Lymphoma Market Report Overview

The B-cell Non-Hodgkins Lymphoma market value for the 15 markets (15M) was $16.1 billion in 2021. NHL refers to a group of cancers that develop in the lymphatic system. NHL is characterized into three types: B-cell, T-cell, and NK lymphocyte lymphomas, of which B-Cell lymphomas are the most common, accounting for approximately 85% of all NHL.  NHL is diagnosed through a biopsy of the swollen lymph node. This is typically followed up with blood tests, a bone marrow aspiration, lumbar puncture, and full body imaging.

The B-Cell NHL market research report includes an assessment of the disease epidemiology and a 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China)  for marketed and pipeline therapies with established mechanisms of action by class, including early to late clinical stage pipeline products, with a launch date assessment by market for B-cell non-Hodgkins lymphoma (NHL).

B-Cell NHL Market Drivers

Cell therapies are expected to capture around 35% of the B-cell NHL market by the end of the forecast period in 2031, reaching $8.4 billion in 8MM sales. In 2021, autologous CAR-T agents constituted 7% of the B-cell NHL market, with further growth expected over the forecast period. Autologous CAR-Ts will only face significant competition if allogeneic agents can demonstrate equivalent or superior efficacy. Allogeneic agents, which can be “off-the-shelf” products, are likely to have a lower price and a simpler manufacturing process.

Kymriah, Yescarta, Breyanzi, and Carteyva will receive label expansions into earlier lines of therapy and into new NHL subtypes. Ineligibility for intensive therapy and stem cell rescue, as well as an inadequate number of long-term remissions, creates a high level of unmet need. There will be a need for “off-the-shelf” products with lower costs and reduced infrastructure requirements.

B-Cell NHL Market Unmet Needs

NHL presents several unmet needs that may be addressed by cell therapies. The unmet need is largely in the R/R setting, where there are limited treatment options for many patients, particularly those who are not candidates for stem cell transplants. The four marketed CAR-Ts have already addressed some of these unmet needs, but some patients relapse after CAR-T therapy and require further treatment options. Autologous CAR-Ts are also prohibitively expensive and require personalized manufacture. Allogeneic pipeline therapies including CAR-Ts and CAR-NKs, which target differential antigens to marketed CAR-Ts, are well positioned to meet this unmet need if they demonstrate sufficient efficacy.

To know more about the unmet needs in the B-Cell NHL market, download a free sample report

B-Cell NHL Market Segmentation by Regions

The key regions in the B-Cell NHL market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021.

B-Cell Non-Hodgkins Lymphoma Market Analysis by Regions, 2021 (%)

For more regional insights on the B-Cell Non-Hodgkins Lymphoma market, download a free report sample

B-Cell NHL Market – Competitive Landscape

Some of the future players in the B-cell NHL market are University College London Autolus Therapeutics Plc, University College London; NIHR Health Technology, Institute of Hematology and Blood Diseases Hospital; Juventas, Sian Wuhan Medical Technology Co Ltd, and Fred Hutchinson Cancer research Center, Celgene Corp. Novartis is the leading sponsor of cell therapy trials in the B-cell NHL market, followed by Kite Pharma and Gilead.

For more insights on companies in the B-cell NHL market, download a free report sample

Segments Covered in the Report

B-Cell NHL Market Regions Outlook (Value, $Billion, 2021-2031)

• North America
• APAC
• Europe
• The Middle East

Reasons to Buy

The report will help to understand:

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication?
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?